Literature DB >> 28779299

Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Kyle T Amber1, Dedee F Murrell2, Enno Schmidt3,4, Pascal Joly5, Luca Borradori6.   

Abstract

Autoimmune subepidermal blistering diseases of the skin and mucosae constitute a large group of sometimes devastating diseases, encompassing bullous pemphigoid, gestational pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, and anti-p200 pemphigoid. Their clinical presentation is polymorphic. These autoimmune blistering diseases are associated with autoantibodies that target distinct components of the basement membrane zone of stratified epithelia. These autoantigens represent structural proteins important for maintenance of dermo-epidermal integrity. Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease of the skin and mucosae. Although the disease typically presents with a generalized blistering eruption associated with itch, atypical variants with either localized bullous lesions or "non-bullous" presentations are observed in approximately 20% of patients. A peculiar form of BP typically associated with pregnancy is pemphigoid gestationis. In anti-p200 pemphigoid, patients present with tense blisters on erythematosus or normal skin resembling BP, with a predilection for acral surfaces. These patients have antibodies targeting the 200-kDa basement membrane protein. Epidermolysis bullosa is a rare autoimmune blistering disease associated with autoantibodies against type VII collagen that can have several phenotypes including a classical form mimicking dystrophic epidermolysis bullosa, an inflammatory presentation mimicking BP, or mucous membrane pemphigoid-like lesions. Mucous membrane pemphigoid (MMP) is the term agreed upon by international consensus for an autoimmune blistering disorder, which affects one or more mucous membrane and may involve the skin. The condition involves a number of different autoantigens in the basement membrane zone. It may result in severe complications from scarring, such as blindness and strictures. Diagnosis of these diseases relies on direct immunofluorescence microscopy studies and immunoserological assays. Management of affected patients is often challenging. We will here review the clinical and immunopathological features as well as the pathophysiology of this group of organ-specific autoimmune diseases. Finally, we will discuss the diagnostic approach and the principles of management in clinical practice.

Entities:  

Keywords:  Anti-p200 pemphigoid; Autoimmune blistering disease; Bullous pemphigoid; Epidermolysis bullosa acquisita; Pemphigoid gestationis

Mesh:

Substances:

Year:  2018        PMID: 28779299     DOI: 10.1007/s12016-017-8633-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  302 in total

1.  Localized bullous pemphigoid in a patient with B-cell lymphoma.

Authors:  C A Egan; S R Florell; J J Zone
Journal:  South Med J       Date:  1999-12       Impact factor: 0.954

2.  Bullous pemphigoid induced by radiotherapy recurring on rechallenge.

Authors:  A Sears; J S Wee; K Misch; J Natkunarajah
Journal:  Clin Exp Dermatol       Date:  2012-06-08       Impact factor: 3.470

3.  Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies.

Authors:  Cassian Sitaru; Cornelia Dähnrich; Christian Probst; Lars Komorowski; Inga Blöcker; Enno Schmidt; Wolfgang Schlumberger; Christian Rose; Winfried Stöcker; Detlef Zillikens
Journal:  Exp Dermatol       Date:  2007-09       Impact factor: 3.960

Review 4.  Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid.

Authors:  R W Saad; N Domloge-Hultsch; K B Yancey; P M Benson; W D James
Journal:  Arch Dermatol       Date:  1992-06

5.  Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol.

Authors:  B Hornschuh; H Hamm; S Wever; T Hashimoto; U Schröder; E B Bröcker; D Zillikens
Journal:  J Am Acad Dermatol       Date:  1997-01       Impact factor: 11.527

6.  Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.

Authors:  Mark C Mochel; Michael E Ming; Sotonye Imadojemu; Tara C Gangadhar; Lynn M Schuchter; Rosalie Elenitsas; Aimee S Payne; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2016-06-01       Impact factor: 1.587

7.  Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.

Authors:  M Megahed; S Schmiedeberg; J Becker; T Ruzicka
Journal:  J Am Acad Dermatol       Date:  2001-08       Impact factor: 11.527

8.  Vesicular pemphigoid.

Authors:  S F Bean; B Michel; N Furey; G Thorne; L Meltzer
Journal:  Arch Dermatol       Date:  1976-10

Review 9.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

10.  Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A.

Authors:  Z Ren; D Y Hsu; J Brieva; N B Silverberg; S M Langan; J I Silverberg
Journal:  Br J Dermatol       Date:  2016-10-29       Impact factor: 9.302

View more
  43 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

Review 3.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 4.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

Review 6.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

7.  BP180 dysfunction triggers spontaneous skin inflammation in mice.

Authors:  Yang Zhang; Bin-Jin Hwang; Zhen Liu; Ning Li; Kendall Lough; Scott E Williams; Jinbo Chen; Susan W Burette; Luis A Diaz; Maureen A Su; Shengxiang Xiao; Zhi Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-04       Impact factor: 11.205

8.  Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS.

Authors:  Farzan Solimani; Dario Didona; Jing Li; Lei Bao; Payal M Patel; Giulia Gasparini; Khalaf Kridin; Emanuele Cozzani; Michael Hertl; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-21       Impact factor: 3.033

9.  Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases.

Authors:  Maike M Holtsche; Nina van Beek; Axel Künstner; Hauke Busch; Detlef Zillikens; Enno Schmidt
Journal:  Acta Derm Venereol       Date:  2021-03-09       Impact factor: 3.875

Review 10.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.